http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 28 Aug 2026 08:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Radiopharm+Theranostics+++For%3A+Aug+28/26993194.html si-local-file:///var/storage/secattach/20260828/26993194.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Radiopharm+Theranostics+++For%3A+Aug+28/26993194.html Fri, 28 Aug 2026 08:00:00 -0400 O.49874572 RAD RADX http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Radiopharm+Theranostics+++For%3A+Aug+28/26993194.html si-local-file:///var/storage/secattach/20260828/26993194.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Radiopharm+Theranostics+++For%3A+Aug+28/26993194.html Fri, 28 Aug 2026 08:00:00 -0400 O.49874572 RAD RADX http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Radiopharm+Theranostics+++For%3A+Aug+28/26993194.html si-local-file:///var/storage/secattach/20260828/26993194.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Radiopharm+Theranostics+++For%3A+Aug+28/26993194.html Fri, 28 Aug 2026 08:00:00 -0400 O.49874572 RAD RADX http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Radiopharm+Theranostics+++For%3A+Aug+27/26985045.html si-local-file:///var/storage/secattach/20260827/26985045.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Radiopharm+Theranostics+++For%3A+Aug+27/26985045.html Thu, 27 Aug 2026 08:00:00 -0400 O.49874572 RAD RADX http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Radiopharm+Theranostics+++For%3A+Aug+27/26985045.html si-local-file:///var/storage/secattach/20260827/26985045.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Radiopharm+Theranostics+++For%3A+Aug+27/26985045.html Thu, 27 Aug 2026 08:00:00 -0400 O.49874572 RAD RADX http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Radiopharm+Theranostics+++For%3A+Aug+27/26985045.html si-local-file:///var/storage/secattach/20260827/26985045.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Radiopharm+Theranostics+++For%3A+Aug+27/26985045.html Thu, 27 Aug 2026 08:00:00 -0400 O.49874572 RAD RADX http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Radiopharm+Theranostics+++For%3A+Aug+26/26977553.html si-local-file:///var/storage/secattach/20260826/26977553.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Radiopharm+Theranostics+++For%3A+Aug+26/26977553.html Wed, 26 Aug 2026 08:00:00 -0400 O.49874572 RAD RADX http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Radiopharm+Theranostics+++For%3A+Aug+26/26977553.html si-local-file:///var/storage/secattach/20260826/26977553.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Radiopharm+Theranostics+++For%3A+Aug+26/26977553.html Wed, 26 Aug 2026 08:00:00 -0400 O.49874572 RAD RADX http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Radiopharm+Theranostics+++For%3A+Aug+26/26977553.html si-local-file:///var/storage/secattach/20260826/26977553.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Radiopharm+Theranostics+++For%3A+Aug+26/26977553.html Wed, 26 Aug 2026 08:00:00 -0400 O.49874572 RAD RADX http://www.streetinsider.com/FDA/Radiopharm+doses+first+patient+in+second+RV-01+trial+cohort/26977188.html <p>Radiopharm Theranostics (ASX: RAD, NASDAQ: RADX) announced it has dosed the first patient in the second cohort of its Phase 1/2a clinical trial of RV-01, also known as 177Lu-Betabart, in patients with B7-H3 expressing solid tumors.</p> <p>The advancement followed a recommendation from the independent Safety and Monitoring Committee to proceed to the 70 mCi dose level of RV-01. The trial is a dose escalation and expansion study evaluating safety, biodistribution, radiation dosimetry, and preliminary anti-tumor activity of RV-01. It is being conducted at clinical centers across the U.S. and aims to enroll 61 participants.</p> <p>Eligible participants include patients with histopathologically confirmed castrate http://www.streetinsider.com/FDA/Radiopharm+doses+first+patient+in+second+RV-01+trial+cohort/26977188.html Wed, 26 Aug 2026 07:00:34 -0400 A.33615634 A.50216911 O.07116439 O.49874572 O.55808949 RAD RADX http://www.streetinsider.com/FDA/Radiopharm+doses+first+patient+in+second+RV-01+trial+cohort/26977188.html <p>Radiopharm Theranostics (ASX: RAD, NASDAQ: RADX) announced it has dosed the first patient in the second cohort of its Phase 1/2a clinical trial of RV-01, also known as 177Lu-Betabart, in patients with B7-H3 expressing solid tumors.</p> <p>The advancement followed a recommendation from the independent Safety and Monitoring Committee to proceed to the 70 mCi dose level of RV-01. The trial is a dose escalation and expansion study evaluating safety, biodistribution, radiation dosimetry, and preliminary anti-tumor activity of RV-01. It is being conducted at clinical centers across the U.S. and aims to enroll 61 participants.</p> <p>Eligible participants include patients with histopathologically confirmed castrate http://www.streetinsider.com/FDA/Radiopharm+doses+first+patient+in+second+RV-01+trial+cohort/26977188.html Wed, 26 Aug 2026 07:00:34 -0400 A.33615634 A.50216911 O.07116439 O.49874572 O.55808949 RAD RADX http://www.streetinsider.com/FDA/Radiopharm+doses+first+patient+in+second+RV-01+trial+cohort/26977188.html <p>Radiopharm Theranostics (ASX: RAD, NASDAQ: RADX) announced it has dosed the first patient in the second cohort of its Phase 1/2a clinical trial of RV-01, also known as 177Lu-Betabart, in patients with B7-H3 expressing solid tumors.</p> <p>The advancement followed a recommendation from the independent Safety and Monitoring Committee to proceed to the 70 mCi dose level of RV-01. The trial is a dose escalation and expansion study evaluating safety, biodistribution, radiation dosimetry, and preliminary anti-tumor activity of RV-01. It is being conducted at clinical centers across the U.S. and aims to enroll 61 participants.</p> <p>Eligible participants include patients with histopathologically confirmed castrate http://www.streetinsider.com/FDA/Radiopharm+doses+first+patient+in+second+RV-01+trial+cohort/26977188.html Wed, 26 Aug 2026 07:00:34 -0400 A.33615634 A.50216911 O.07116439 O.49874572 O.55808949 RAD RADX http://www.streetinsider.com/FDA/Radiopharm+doses+first+patient+in+second+RV-01+trial+cohort/26977188.html <p>Radiopharm Theranostics (ASX: RAD, NASDAQ: RADX) announced it has dosed the first patient in the second cohort of its Phase 1/2a clinical trial of RV-01, also known as 177Lu-Betabart, in patients with B7-H3 expressing solid tumors.</p> <p>The advancement followed a recommendation from the independent Safety and Monitoring Committee to proceed to the 70 mCi dose level of RV-01. The trial is a dose escalation and expansion study evaluating safety, biodistribution, radiation dosimetry, and preliminary anti-tumor activity of RV-01. It is being conducted at clinical centers across the U.S. and aims to enroll 61 participants.</p> <p>Eligible participants include patients with histopathologically confirmed castrate http://www.streetinsider.com/FDA/Radiopharm+doses+first+patient+in+second+RV-01+trial+cohort/26977188.html Wed, 26 Aug 2026 07:00:34 -0400 A.33615634 A.50216911 O.07116439 O.49874572 O.55808949 RAD RADX http://www.streetinsider.com/FDA/Radiopharm+doses+first+patient+in+second+RV-01+trial+cohort/26977188.html <p>Radiopharm Theranostics (ASX: RAD, NASDAQ: RADX) announced it has dosed the first patient in the second cohort of its Phase 1/2a clinical trial of RV-01, also known as 177Lu-Betabart, in patients with B7-H3 expressing solid tumors.</p> <p>The advancement followed a recommendation from the independent Safety and Monitoring Committee to proceed to the 70 mCi dose level of RV-01. The trial is a dose escalation and expansion study evaluating safety, biodistribution, radiation dosimetry, and preliminary anti-tumor activity of RV-01. It is being conducted at clinical centers across the U.S. and aims to enroll 61 participants.</p> <p>Eligible participants include patients with histopathologically confirmed castrate http://www.streetinsider.com/FDA/Radiopharm+doses+first+patient+in+second+RV-01+trial+cohort/26977188.html Wed, 26 Aug 2026 07:00:34 -0400 A.33615634 A.50216911 O.07116439 O.49874572 O.55808949 RAD RADX http://www.streetinsider.com/FDA/Radiopharm+doses+first+patient+in+second+RV-01+trial+cohort/26977188.html <p>Radiopharm Theranostics (ASX: RAD, NASDAQ: RADX) announced it has dosed the first patient in the second cohort of its Phase 1/2a clinical trial of RV-01, also known as 177Lu-Betabart, in patients with B7-H3 expressing solid tumors.</p> <p>The advancement followed a recommendation from the independent Safety and Monitoring Committee to proceed to the 70 mCi dose level of RV-01. The trial is a dose escalation and expansion study evaluating safety, biodistribution, radiation dosimetry, and preliminary anti-tumor activity of RV-01. It is being conducted at clinical centers across the U.S. and aims to enroll 61 participants.</p> <p>Eligible participants include patients with histopathologically confirmed castrate http://www.streetinsider.com/FDA/Radiopharm+doses+first+patient+in+second+RV-01+trial+cohort/26977188.html Wed, 26 Aug 2026 07:00:34 -0400 A.33615634 A.50216911 O.07116439 O.49874572 O.55808949 RAD RADX http://www.streetinsider.com/FDA/Radiopharm+doses+first+patient+in+second+RV-01+trial+cohort/26977188.html <p>Radiopharm Theranostics (ASX: RAD, NASDAQ: RADX) announced it has dosed the first patient in the second cohort of its Phase 1/2a clinical trial of RV-01, also known as 177Lu-Betabart, in patients with B7-H3 expressing solid tumors.</p> <p>The advancement followed a recommendation from the independent Safety and Monitoring Committee to proceed to the 70 mCi dose level of RV-01. The trial is a dose escalation and expansion study evaluating safety, biodistribution, radiation dosimetry, and preliminary anti-tumor activity of RV-01. It is being conducted at clinical centers across the U.S. and aims to enroll 61 participants.</p> <p>Eligible participants include patients with histopathologically confirmed castrate http://www.streetinsider.com/FDA/Radiopharm+doses+first+patient+in+second+RV-01+trial+cohort/26977188.html Wed, 26 Aug 2026 07:00:34 -0400 A.33615634 A.50216911 O.07116439 O.49874572 O.55808949 RAD RADX http://www.streetinsider.com/Press+Releases/Radiopharm+Theranostics+Doses+First+Patient+in+Second+Cohort+of+Phase+12a+Clinical+Trial+of+BetaBart+%28RV-01%29+in+B7-H3+Expressing+Solid+Tumors/26977178.html <p>SYDNEY, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that it has dosed the first patient in the second cohort of its First-In-Human (FIH) Phase 1/2a clinical trial of RV-01 (177Lu-Betabart) in patients with B7-H3 expressing tumors. This follows a positive recommendation from the Safety and Monitoring Committee (SMC), an independent multidisciplinary committee, to advance to the 70 mCi dose of RV-01.</p> <p>RV-01 is a 177Lutetium-tagged engineered monoclonal antibody, designed http://www.streetinsider.com/Press+Releases/Radiopharm+Theranostics+Doses+First+Patient+in+Second+Cohort+of+Phase+12a+Clinical+Trial+of+BetaBart+%28RV-01%29+in+B7-H3+Expressing+Solid+Tumors/26977178.html Wed, 26 Aug 2026 07:00:00 -0400 A.33615634 A.50216911 O.07116439 O.49874572 O.55808949 RAD RADX http://www.streetinsider.com/Press+Releases/Radiopharm+Theranostics+Doses+First+Patient+in+Second+Cohort+of+Phase+12a+Clinical+Trial+of+BetaBart+%28RV-01%29+in+B7-H3+Expressing+Solid+Tumors/26977178.html <p>SYDNEY, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that it has dosed the first patient in the second cohort of its First-In-Human (FIH) Phase 1/2a clinical trial of RV-01 (177Lu-Betabart) in patients with B7-H3 expressing tumors. This follows a positive recommendation from the Safety and Monitoring Committee (SMC), an independent multidisciplinary committee, to advance to the 70 mCi dose of RV-01.</p> <p>RV-01 is a 177Lutetium-tagged engineered monoclonal antibody, designed http://www.streetinsider.com/Press+Releases/Radiopharm+Theranostics+Doses+First+Patient+in+Second+Cohort+of+Phase+12a+Clinical+Trial+of+BetaBart+%28RV-01%29+in+B7-H3+Expressing+Solid+Tumors/26977178.html Wed, 26 Aug 2026 07:00:00 -0400 A.33615634 A.50216911 O.07116439 O.49874572 O.55808949 RAD RADX http://www.streetinsider.com/Press+Releases/Radiopharm+Theranostics+Doses+First+Patient+in+Second+Cohort+of+Phase+12a+Clinical+Trial+of+BetaBart+%28RV-01%29+in+B7-H3+Expressing+Solid+Tumors/26977178.html <p>SYDNEY, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that it has dosed the first patient in the second cohort of its First-In-Human (FIH) Phase 1/2a clinical trial of RV-01 (177Lu-Betabart) in patients with B7-H3 expressing tumors. This follows a positive recommendation from the Safety and Monitoring Committee (SMC), an independent multidisciplinary committee, to advance to the 70 mCi dose of RV-01.</p> <p>RV-01 is a 177Lutetium-tagged engineered monoclonal antibody, designed http://www.streetinsider.com/Press+Releases/Radiopharm+Theranostics+Doses+First+Patient+in+Second+Cohort+of+Phase+12a+Clinical+Trial+of+BetaBart+%28RV-01%29+in+B7-H3+Expressing+Solid+Tumors/26977178.html Wed, 26 Aug 2026 07:00:00 -0400 A.33615634 A.50216911 O.07116439 O.49874572 O.55808949 RAD RADX http://www.streetinsider.com/Press+Releases/Radiopharm+Theranostics+Doses+First+Patient+in+Second+Cohort+of+Phase+12a+Clinical+Trial+of+BetaBart+%28RV-01%29+in+B7-H3+Expressing+Solid+Tumors/26977178.html <p>SYDNEY, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that it has dosed the first patient in the second cohort of its First-In-Human (FIH) Phase 1/2a clinical trial of RV-01 (177Lu-Betabart) in patients with B7-H3 expressing tumors. This follows a positive recommendation from the Safety and Monitoring Committee (SMC), an independent multidisciplinary committee, to advance to the 70 mCi dose of RV-01.</p> <p>RV-01 is a 177Lutetium-tagged engineered monoclonal antibody, designed http://www.streetinsider.com/Press+Releases/Radiopharm+Theranostics+Doses+First+Patient+in+Second+Cohort+of+Phase+12a+Clinical+Trial+of+BetaBart+%28RV-01%29+in+B7-H3+Expressing+Solid+Tumors/26977178.html Wed, 26 Aug 2026 07:00:00 -0400 A.33615634 A.50216911 O.07116439 O.49874572 O.55808949 RAD RADX http://www.streetinsider.com/Press+Releases/Radiopharm+Theranostics+Doses+First+Patient+in+Second+Cohort+of+Phase+12a+Clinical+Trial+of+BetaBart+%28RV-01%29+in+B7-H3+Expressing+Solid+Tumors/26977178.html <p>SYDNEY, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that it has dosed the first patient in the second cohort of its First-In-Human (FIH) Phase 1/2a clinical trial of RV-01 (177Lu-Betabart) in patients with B7-H3 expressing tumors. This follows a positive recommendation from the Safety and Monitoring Committee (SMC), an independent multidisciplinary committee, to advance to the 70 mCi dose of RV-01.</p> <p>RV-01 is a 177Lutetium-tagged engineered monoclonal antibody, designed http://www.streetinsider.com/Press+Releases/Radiopharm+Theranostics+Doses+First+Patient+in+Second+Cohort+of+Phase+12a+Clinical+Trial+of+BetaBart+%28RV-01%29+in+B7-H3+Expressing+Solid+Tumors/26977178.html Wed, 26 Aug 2026 07:00:00 -0400 A.33615634 A.50216911 O.07116439 O.49874572 O.55808949 RAD RADX http://www.streetinsider.com/Press+Releases/Radiopharm+Theranostics+Doses+First+Patient+in+Second+Cohort+of+Phase+12a+Clinical+Trial+of+BetaBart+%28RV-01%29+in+B7-H3+Expressing+Solid+Tumors/26977178.html <p>SYDNEY, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that it has dosed the first patient in the second cohort of its First-In-Human (FIH) Phase 1/2a clinical trial of RV-01 (177Lu-Betabart) in patients with B7-H3 expressing tumors. This follows a positive recommendation from the Safety and Monitoring Committee (SMC), an independent multidisciplinary committee, to advance to the 70 mCi dose of RV-01.</p> <p>RV-01 is a 177Lutetium-tagged engineered monoclonal antibody, designed http://www.streetinsider.com/Press+Releases/Radiopharm+Theranostics+Doses+First+Patient+in+Second+Cohort+of+Phase+12a+Clinical+Trial+of+BetaBart+%28RV-01%29+in+B7-H3+Expressing+Solid+Tumors/26977178.html Wed, 26 Aug 2026 07:00:00 -0400 A.33615634 A.50216911 O.07116439 O.49874572 O.55808949 RAD RADX http://www.streetinsider.com/Press+Releases/Radiopharm+Theranostics+Doses+First+Patient+in+Second+Cohort+of+Phase+12a+Clinical+Trial+of+BetaBart+%28RV-01%29+in+B7-H3+Expressing+Solid+Tumors/26977178.html <p>SYDNEY, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that it has dosed the first patient in the second cohort of its First-In-Human (FIH) Phase 1/2a clinical trial of RV-01 (177Lu-Betabart) in patients with B7-H3 expressing tumors. This follows a positive recommendation from the Safety and Monitoring Committee (SMC), an independent multidisciplinary committee, to advance to the 70 mCi dose of RV-01.</p> <p>RV-01 is a 177Lutetium-tagged engineered monoclonal antibody, designed http://www.streetinsider.com/Press+Releases/Radiopharm+Theranostics+Doses+First+Patient+in+Second+Cohort+of+Phase+12a+Clinical+Trial+of+BetaBart+%28RV-01%29+in+B7-H3+Expressing+Solid+Tumors/26977178.html Wed, 26 Aug 2026 07:00:00 -0400 A.33615634 A.50216911 O.07116439 O.49874572 O.55808949 RAD RADX http://www.streetinsider.com/Globe+Newswire/Radiopharm+Theranostics+Doses+First+Patient+in+Second+Cohort+of+Phase+12a+Clinical+Trial+of+BetaBart+%28RV-01%29+in+B7-H3+Expressing+Solid+Tumors/26977178.html <p>SYDNEY, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that it has dosed the first patient in the second cohort of its First-In-Human (FIH) Phase 1/2a clinical trial of RV-01 (177Lu-Betabart) in patients with B7-H3 expressing tumors. This follows a positive recommendation from the Safety and Monitoring Committee (SMC), an independent multidisciplinary committee, to advance to the 70 mCi dose of RV-01.</p> <p>RV-01 is a 177Lutetium-tagged engineered monoclonal antibody, designed http://www.streetinsider.com/Globe+Newswire/Radiopharm+Theranostics+Doses+First+Patient+in+Second+Cohort+of+Phase+12a+Clinical+Trial+of+BetaBart+%28RV-01%29+in+B7-H3+Expressing+Solid+Tumors/26977178.html Wed, 26 Aug 2026 07:00:00 -0400 A.33615634 A.50216911 O.07116439 O.49874572 O.55808949 RAD RADX http://www.streetinsider.com/Globe+Newswire/Radiopharm+Theranostics+Doses+First+Patient+in+Second+Cohort+of+Phase+12a+Clinical+Trial+of+BetaBart+%28RV-01%29+in+B7-H3+Expressing+Solid+Tumors/26977178.html <p>SYDNEY, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that it has dosed the first patient in the second cohort of its First-In-Human (FIH) Phase 1/2a clinical trial of RV-01 (177Lu-Betabart) in patients with B7-H3 expressing tumors. This follows a positive recommendation from the Safety and Monitoring Committee (SMC), an independent multidisciplinary committee, to advance to the 70 mCi dose of RV-01.</p> <p>RV-01 is a 177Lutetium-tagged engineered monoclonal antibody, designed http://www.streetinsider.com/Globe+Newswire/Radiopharm+Theranostics+Doses+First+Patient+in+Second+Cohort+of+Phase+12a+Clinical+Trial+of+BetaBart+%28RV-01%29+in+B7-H3+Expressing+Solid+Tumors/26977178.html Wed, 26 Aug 2026 07:00:00 -0400 A.33615634 A.50216911 O.07116439 O.49874572 O.55808949 RAD RADX